(rel)-Oxaliplatin
(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 63121-00-6
- Formule: C8H14N2O4Pt
- Masse moléculaire:397.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
(rel)-Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1].
(rel)-Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2].
(rel)-Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCC, HCCLM3 and Hep3B cells
-
Concentration:24, 48 and 72 hours
-
Incubation Time:2, 4, 8, 16, 32, 64 and 128 μM
-
Result:Decreased cell viability in a dose- and time-dependent manner.
-
Cell Line:HCCLM3 and Hep3B cells
-
Concentration:48 hours
-
Incubation Time:10 μM
-
Result:Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.
-
Cell Line:HCCLM3 and Hep3B cells
-
Concentration:24 hours
-
Incubation Time:10 μM
-
Result:Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:5 and 10 mg/kg
-
Administration:Intraperitoneal injection; for 32 days
-
Result:Reduced tumor volume in HCCLM3 tumor xenografts.
Chemical Information
-
CAS No. 63121-00-6
-
Masse moléculaire 397.29
-
Formule C8H14N2O4Pt
-
SMILES
O=C1[O-][Pt+2]2([O-]C1=O)[NH2][C@@](CCCC3)([H])[C@]3([H])[NH2]2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Woynarowski JM, et, al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 2000 Nov;58(5):920-7. [Content Brief]
[2]. Wang Z, et, al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604. [Content Brief]
[3]. Pendyala L, et, al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(rel)-Oxaliplatin Related Classifications
HY-17371A Related Classifications
Powered by Bioz